Skip to main content
HighlightsHighlights Archive

Novel blood tests could transform NHS dementia diagnosis in next 5 years

By April 9, 2024No Comments

UK scientists are gearing up to lead clinical trials for blood tests that could transform dementia diagnosis within the NHS. Teams from University College London (UCL) and the University of Oxford aim to provide the necessary evidence for validating dementia blood tests for NHS utilisation within the next five years.

The READ-OUT team, spearheaded by Dr. Vanessa Raymont and Dr. Ivan Koychev from the University of Oxford, along with Professor James Rowe from the University of Cambridge, will oversee the evaluation of both existing and novel blood tests designed for different types of dementia, such as Alzheimer’s disease, vascular dementia, frontotemporal dementia, and dementia with Lewy bodies. They will also determine the efficacy of these blood tests in detecting the diseases at various stages.

Meanwhile, the ADAPT team, led by UCL’s Professor Jonathan Schott and Dr. Ashvini Keshavan, will concentrate on assessing the most promising biomarker for Alzheimer’s disease – p-tau217 – to ascertain whether its measurement in blood can expedite the diagnosis of Alzheimer’s disease, particularly in individuals with early dementia and memory issues.

Both research teams will recruit participants nationwide, ensuring that their findings are relevant and applicable to the entire UK population.

The two research teams make up the Blood Biomarker Challenge, which has received support from:

  • Alzheimer’s Society
  • Alzheimer’s Research UK
  • National Institute for Health and Care Research
  • Gates Ventures
  • People’s Postcode Lottery
Ben Kemp